Clinical Utility of ANA-ELISA Vs ANA-immunofluorescence in Connective Tissue Diseases

Overview

Journal Sci Rep

Specialty Science

Date 2021 Apr 16

PMID 33859213

Citations 8

Authors

Omar Suhail Alsaed

Laith Ishaq Alamlih

Omar Al-Radideh

Prem Chandra

Samar Alemadi

Abdul-Wahab Al-Allaf

Affiliations

Soon will be listed here.

Abstract

We investigated the performance of ANA-ELISA for CTDs screening and diagnosis and comparing it to the conventional ANA-IIF. ANA-ELISA is a solid-phase immune assay includes 17 ANA-targeted recombinant antigens; dsDNA, Sm-D, Rib-P, PCNA, U1-RNP (70, A, C), SS-A/Ro (52 and 60), SS-B/La, Centromere B, Scl-70, Fibrillarin, RNA Polymerase III, Jo-1, Mi-2, and PM-Scl. During the period between March till December 2016 all requests for ANA from primary, secondary, and tertiary care centers were processed with both techniques; ANA-IIF and ANA-ELISA. The electronic medical record of these patients was reviewed looking for CTD diagnosis documented by the Senior rheumatologist. SPSS 22 is used for analysis. Between March and December 2016, a total of 12,439 ANA tests were requested. 1457 patients were assessed by the rheumatologist and included in the analysis. At a cut-off ratio ≥ 1.0 for ANA-ELISA and a dilutional titre ≥ 1:80 for ANA-IIF, the sensitivity of ANA-IIF and ANA-ELISA for all CTDs were 63.3% vs 74.8% respectively. For the SLE it was 64.3% vs 76.9%, Sjogren's Syndrome was 50% vs 76.9% respectively. The overall specificity of ANA-ELISA was 89.05%, which was slightly better than ANA-IIF 86.72%. The clinical performance of ANA-ELISA for CTDs screening showed better sensitivity and specificity as compared to the conventional ANA-IIF in our cohort.

Citing Articles

International Consensus on ANA Patterns (ICAP) Classification Tree Revisited: A Single Centre Report on Four Nuclear Patterns from a Tertiary Care Centre in India.

Ranjan A, Ahmad S, Kumar S, Patra P, Kumar A, Prakash J EJIFCC. 2025; 36(1):37-49.

PMID: 40061060 PMC: 11886623.

Duplex Vertical-Flow Rapid Tests for Point-of-Care Detection of Anti-dsDNA and Anti-Nuclear Autoantibodies.

Lei R, Arain H, Wang D, Arunachalam J, Saxena R, Mohan C Biosensors (Basel). 2024; 14(2).

PMID: 38392017 PMC: 10887294. DOI: 10.3390/bios14020098.

Phospholipase C Zeta 1 (PLCZ1): The Function and Potential for Fertility Assessment and In Vitro Embryo Production in Cattle and Horses.

Gonzalez-Castro R, Carnevale E Vet Sci. 2023; 10(12).

PMID: 38133249 PMC: 10747197. DOI: 10.3390/vetsci10120698.

Basic Investigations in Pediatric Rheumatology.

Banday A, Nisar R, Patra P, Ahmad I, Gupta A Indian J Pediatr. 2023; 91(9):927-933.

PMID: 37676468 DOI: 10.1007/s12098-023-04821-4.

Enzyme-Linked Immunosorbent Assay: Types and Applications.

Hayrapetyan H, Tran T, Tellez-Corrales E, Madiraju C Methods Mol Biol. 2023; 2612:1-17.

PMID: 36795355 DOI: 10.1007/978-1-0716-2903-1_1.

References

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T . RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009; 60(7):2193-200. DOI: 10.1002/art.24621. View

Baronaite R, Engelhart M, Mork Hansen T, Thamsborg G, Jensen H, Stender S . A comparison of anti-nuclear antibody quantification using automated enzyme immunoassays and immunofluorescence assays. Autoimmune Dis. 2014; 2014:534759. PMC: 3926329. DOI: 10.1155/2014/534759. View

Solomon D, Kavanaugh A, Schur P . Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002; 47(4):434-44. DOI: 10.1002/art.10561. View

Tan E, FELTKAMP T, Smolen J, Butcher B, Dawkins R, Fritzler M . Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997; 40(9):1601-11. DOI: 10.1002/art.1780400909. View

Maddison P, Stephens C, Briggs D, Welsh K, Harvey G, Whyte J . Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group. Medicine (Baltimore). 1993; 72(2):103-12. DOI: 10.1097/00005792-199303000-00004. View

Meroni P, Schur P . ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010; 69(8):1420-2. DOI: 10.1136/ard.2009.127100. View

Orme M, Andalucia C, Sjolander S, Bossuyt X . A comparison of a fluorescence enzyme immunoassay versus indirect immunofluorescence for initial screening of connective tissue diseases: Systematic literature review and meta-analysis of diagnostic test accuracy studies. Best Pract Res Clin Rheumatol. 2019; 32(4):521-534. DOI: 10.1016/j.berh.2019.03.005. View

Mahler M, Dervieux T . Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies. Ann Rheum Dis. 2014; 73(7):e36. DOI: 10.1136/annrheumdis-2014-205324. View

Fritzler M, Hanson C, Miller J, Eystathioy T . Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate. J Clin Lab Anal. 2002; 16(2):103-8. PMC: 6808092. DOI: 10.1002/jcla.10026. View

10.

De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D . Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev. 2011; 10(12):801-8. DOI: 10.1016/j.autrev.2011.06.005. View

11.

Lakota K, Thallinger G, Sodin-Semrl S, Rozman B, Ambrozic A, Tomsic M . International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis Res Ther. 2012; 14(1):R2. PMC: 3392788. DOI: 10.1186/ar3550. View

12.

De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D . Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev. 2012; 12(2):137-43. DOI: 10.1016/j.autrev.2012.02.013. View

13.

. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. Arthritis Rheum. 2002; 47(4):429-33. DOI: 10.1002/art.10381. View

14.

Okada N, Mimori T, Mukai R, Kashiwagi H, Hardin J . Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol. 1987; 138(10):3219-23. View

15.

Robier C, Amouzadeh-Ghadikolai O, Stettin M, Reicht G . Comparison of the clinical utility of the Elia CTD Screen to indirect immunofluorescence on Hep-2 cells. Clin Chem Lab Med. 2015; 54(8):1365-70. DOI: 10.1515/cclm-2015-1051. View

16.

Alderuccio F, Chan E, Tan E . Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med. 1991; 173(4):941-52. PMC: 2190817. DOI: 10.1084/jem.173.4.941. View

17.

Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari P, Doria A . Anti-Jo-1 antibodies. Autoimmunity. 2005; 38(1):73-8. DOI: 10.1080/08916930400022640. View

18.

Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari P . Anti-Mi-2 antibodies. Autoimmunity. 2005; 38(1):79-83. DOI: 10.1080/08916930400022681. View

19.

Colglazier C, Sutej P . Laboratory testing in the rheumatic diseases: a practical review. South Med J. 2005; 98(2):185-91. DOI: 10.1097/01.SMJ.0000153572.22346.E9. View

20.

Jeong S, Hwang H, Roh J, Shim J, Kim J, Kim G . Evaluation of an Automated Screening Assay, Compared to Indirect Immunofluorescence, an Extractable Nuclear Antigen Assay, and a Line Immunoassay in a Large Cohort of Asian Patients with Antinuclear Antibody-Associated Rheumatoid Diseases: A.... J Immunol Res. 2018; 2018:9094217. PMC: 5954951. DOI: 10.1155/2018/9094217. View